Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19 : a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial

Keir, H R, Long, M B, Abo-Leyah, H, Giam, Y H, Vadiveloo, T, Pembridge, T, Hull, R C, Delgado, L, Band, M, McLaren-Neil, F, Adamson, S, Lahnsteiner, E, Gilmour, A, Hughes, C, New, B J, Connell, D, Dowey, R, Turton, H, Richardson, H, Cassidy, D, Cooper, J, Suntharalingam, J, Diwakar, L, Russell, P, Underwood, J, Hicks, A, Dosanjh, D P, Sage, B, Dhasmana, D, Spears, M, Thompson, AA R, Brightling, C, Smith, A, Patel, M, George, J, Condliffe, A M, Shoemark, A, MacLennan, G, Chalmers, J D & STOP-COVID19 Investigators 2022, 'Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19 : a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial', The Lancet. Respiratory medicine, vol. 10, no. 12, pp. 1119-1128. https://doi.org/10.1016/S2213-2600(22)00261-2